[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"King Hussein Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,82,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100639567","ct-guided-vs-conventional-dlt-sizing-in-thoracic-surgery-100639567",false,"NCT07575763","CT-Guided vs Conventional DLT Sizing in Thoracic Surgery","CT-Guided Versus Traditional Selection of Double-Lumen Tube Size for One-Lung Ventilation in Thoracic Surgery: A Prospective Study","CTDLT-SIZE","Inclusion Criteria:\n\n1. Adult patients (≥18 years) scheduled for elective thoracic surgery requiring one-lung ventilation.\n2. Availability of preoperative thoracic CT imaging.\n3. Procedures requiring placement of a left-sided DLT.\n4. Patient who has a normal pulmonary function test.\n\nExclusion Criteria:\n\n1. Previous tracheal surgery\n2. Patient with difficult airway whom need bronchial blocker.\n3. Emergency thoracic procedures.\n4. Incomplete intraoperative or imaging data.\n5. Patient with severe obstruction or restriction.\n6. Pediatric patient","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized, single-blinded controlled trial designed to compare CT-guided versus conventional methods for selecting double-lumen tube (DLT) size in patients undergoing thoracic surgery requiring one-lung ventilation",[27,28],"Thoracic Surgery","One-lung Ventilation",[30,31,32,33],"Double-lumen tube","Thoracic anesthesia","CT-guided intubation","One-lung ventilation","NOT_YET_RECRUITING","2026-05-08",{"date":37,"type":38},"2026-05-13","ACTUAL",{"date":40,"type":21},"2026-05-15",{"date":42,"type":21},"2028-08-01",{"name":44,"class":45},"King Hussein Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100635482","effectiveness-of-09-normal-saline-soaking-in-managing-acute-radiation-dermatitis-100635482","NCT07553260","Effectiveness of 0.9% Normal Saline Soaking in Managing Acute Radiation Dermatitis","The Effectiveness of Saline Soaks in Managing Acute Radiation Dermatitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Patients receiving definitive radiotherapy for sarcomas or head and neck cancer (primary or postoperative treatment)\n* Planned radiation dose between 60-70 Gy according to disease-specific protocols\n* No prior history of malignancy other than sarcomas\n* Ability and willingness to comply with study procedures (\\>90% expected adherence)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients receiving palliative radiotherapy\n* Known pre-existing skin disorders affecting radiation area (e.g., systemic lupus erythematosus, scleroderma)\n* ECOG performance status ≥2\n* Previous radiotherapy to the same treatment field\n* Any condition that, in the investigator's judgment, may interfere with participation or wound healing assessment",{"count":55,"type":21},150,[24],"The goal of this clinical trial is to learn if normal saline soaks can reduce the severity of acute radiation dermatitis in patients with sarcomas or head and neck cancer receiving radiotherapy. It will also learn if saline soaks can improve wound healing and reduce treatment interruptions caused by skin toxicity. The main questions it aims to answer are:\n\n1. Does the application of normal saline soaks reduce the severity of acute radiation dermatitis according to CTCAE Version 5.0?\n2. Does the use of normal saline soaks improve wound healing time and reduce the frequency and duration of radiotherapy interruptions? Researchers will compare standard care plus saline soaks (intervention group) to standard care alone (control group) to see if saline soaks reduce skin reaction severity and improve clinical outcomes.\n\nParticipants will:\n\n1. Be randomly assigned to receive either standard care alone or standard care with daily saline soaks\n2. Apply saline-soaked gauze to the affected radiation area for 5-10 minutes once daily (intervention group only)\n3. Attend weekly clinic visits for skin assessment during radiotherapy\n4. Be assessed for skin reaction severity, wound healing, and treatment interruptions at baseline, after 4 weeks, and 2 weeks after completing treatment",[59,60,61],"Acute Radiation Dermatitis","Head and Neck Cancer (H&N)","Sarcomas",[63,64,65,66,67,68,69,70,71,72,73],"Dermatitis, Radiation-Induced","Skin Diseases, Radiation-Induced","Radiotherapy","Head and Neck Neoplasms","Sarcoma","Sodium Chloride","Wound Healing","Skin Care","Moist Desquamation","Supportive Care","Treatment Outcome","2026-04-20",{"date":76,"type":38},"2026-04-27",{"date":78,"type":21},"2026-05",{"date":80,"type":21},"2027-06",{"name":44,"class":45},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100621498","mb-cart191-in-relapsedrefractory-acute-lymphoblastic-leukemia-100621498","NCT07371403","MB-CART19.1 in Relapsed\u002FRefractory Acute Lymphoblastic Leukemia","MB-CART19.1 in Patients With Relapsed\u002FRefractory CD19-positive B Cell Acute Lymphoblastic Leukemia: A Feasibility Study","Inclusion Criteria:\n\n* Age ≥ 1 year as long as if deemed fit by treating investigator\n* CD19 expression must be detected (≥20%) on the malignant cells by flow cytometry.\n* Patients with relapsed or refractory disease with \\>5% blasts in the bone marrow after at least one frontline and one salvage chemotherapy regimen. For patients with Philadelphia-positive disease, a second generation or higher TKI must have been utilized in one of the treatment lines.\n* Patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active graft vs host disease, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.\n* Estimated life expectancy \\> 12 weeks\n* Karnofsky or Lansky (age dependent) performance score ≥ 60\n* Patients and\u002For parents must give their written informed consent\u002Fassent.\n* CNS and\u002For testicular involvement are allowed, only if cleared and in the presence of systemic involvement.\n\nExclusion Criteria:\n\n* Rapidly progressive, uncontrolled disease as assessed by the treating physician and\u002For principal investigator.\n* Persistent extramedullary disease.\n* Isolated CNS and\u002For testicular disease.\n* Current autoimmune disease, or history of autoimmune disease with potential CNS involvement\n* Active hepatitis B, C or HIV\n* Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis)\n* History of an additional malignancy (≤ 3 years) other than non-melanoma skin cancer or carcinoma in situ.\n* Pulmonary function: Patients with pre-existing severe lung disease (FEV1 or FVC \\\u003C 65%) or an oxygen requirement of \\>28% O2 FiO2 or active pulmonary infection.\n* Cardiac function: Left ventricular ejection fraction \\\u003C50% by echocardiography\n* Renal function: Creatinine clearance \\\u003C50 mL\u002Fmin\u002F1.73 m2\n* Liver function: patients with serum bilirubin ≥3 times upper limit of or AST or ALT \\> 5 times upper limit of normal, unless due to leukemic liver infiltration as determined by the investigators.\n* Pregnant or breast-feeding females\n* Medications: systemic chemotherapies, corticosteroids with the exception of physiologic replacement dosing (\\\u003C0.5 mg\u002Fkg\u002Fday of methylprednicone), tyrosine kinase inhibitors (TKI) within 7 days prior to leukapheresis, Fludarabine\u002Fclofarabine or immunosuppressive drugs and antibodies (e.g. rituximab, blinatumomab) or investigational drugs or donor lymphocyte","1 Year",{"count":91,"type":21},12,[24],"Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.",[95,96,97,98,99],"Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia Recurrent","Acute Lymphoblastic Leukemia Refractory","Acute Lymphoblastic Leukemia Not Having Achieved Remission","Acute Lymphoblastic Leukemia With Failed Remission",[101,102,17,103,104,105],"CAR-T","MB-CART19.1","acute lymphoblastic leukemia","relapsed acute lymphoblastic leukemia","refractory acute lymphoblastic leukemia","RECRUITING","2026-03-24",{"date":109,"type":38},"2026-03-25",{"date":111,"type":21},"2026-02",{"date":113,"type":21},"2029-01",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100613786","phase-2-study-of-cart-cell-mb-cart191-in-patients-with-relapsed-or-refractory-cd19-positive-nhl-100613786","NCT07271121","Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","A Phase II Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","Inclusion Criteria:\n\n1. Eligible patients with a diagnosis of aggressive NHL:\n\n   1. Patients after progression on at least one standard chemotherapy and one salvage regimen or\n   2. Patients considered for alloSCT but are found ineligible or\n   3. Patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.\n2. Patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared at the time of inclusion.\n3. CD19 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry\n4. Age \\> 18 year up to 75 years old (if deemed fit by treating investigator);\n5. Baseline absolute CD3+ T cell count by FACS ≥100\u002Fµl;\n6. ECOG performance score of 0-2 at screening;\n7. No active Hepatitis B, Hepatitis C, HIV I\u002FII\n8. No childbearing potential or negative pregnancy test at screening within 7 days from starting lymphodepletion chemotherapy and before bridging chemotherapy in women with childbearing potential;\n9. Signed and dated informed consent, before conduct of any trial-specific procedure.\n\nExclusion Criteria:\n\n1. Residual CNS disease\n2. Current autoimmune disease, or history of autoimmune disease with potential CNS involvement;\n3. Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis)\n4. History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years;\n5. Pulmonary function: Patients with pre-existing severe lung disease or DLCO of less than 50% or active pulmonary infiltrates on imaging studies.\n6. Cardiac function: left ventricular ejection faction \\\u003C50% by echocardiogram,\n7. Renal function: Creatinine clearance \\\u003C50 mL\u002Fmin\u002F1.73 m2, by Cockcroft-Gault formula (Cockcroft and Gault 1976) for patients ≥18 years.\n8. Liver function: patients with serum bilirubin ≥3 times upper limit of or AST or ALT \\> 5 times upper limit of normal, unless due to lymphoma liver infiltration in the estimation of the investigator.\n9. Rapidly progressive disease that in the estimation of the investigator would compromise ability to complete study therapy;\n10. Pregnant or breast-feeding females\n11. Medications: systemic chemotherapies, corticosteroids with the exception of physiologic replacement dosing, Fludarabine\u002Fclofarabine or immunosuppressive (Calcineurin inhibitors) drugs and antibodies or investigational drugs or donor lymphocyte transfusions or radiation therapy within 30 days prior to apheresis, and rituximab within 2 weeks with the exception of Intrathecal chemotherapy is allowed prior to treatment, but should be discontinued 10 days prior to-CART19 infusion to limit the risk of neurotoxicities;\n12. Patients of child-bearing or fathering potential not willing to practice an effective form of birth control from the time of enrollment and for three months after dosing of the CARTs;\n13. Concurrent participation in another interventional trial that could interact with this trial, e.g. CAR T trials.\n14. Other investigational treatment within 4 weeks before CARTs infusion;\n15. Cerebral dysfunction, legal incapacity of adult patients;\n16. Committal to an institution on judicial or official order.","75 Years",{"count":124,"type":21},26,[126],"PHASE2","This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients \\>18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose of MB-CART-19.1 and will be followed for 12 months and evaluated for efficacy and safety.",[129],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed",[129,131],"MB-CART-19.1","2025-12-06",{"date":134,"type":38},"2025-12-09",{"date":136,"type":38},"2025-02-12",{"date":138,"type":21},"2028-06-30",{"name":44,"class":45},""]